Viewing Study NCT02289456

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:16 PM
Ignite Modification Date: 2026-06-03 @ 11:06 AM
Study NCT ID: NCT02289456
Status: COMPLETED
Last Update Posted: 2018-12-07
First Post: 2014-11-10
Is Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase II Safety and Tolerability Trial With Nab-Paclitaxel Plus Carboplatin Followed by Nab-Paclitaxel for First Line Treatment of NSCLC Subjects With ECOG PS 2
Sponsor: Celgene
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small-Cell Lung View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase II, LOCALLY ADVANCED OR METASTATIC NON SMALL View
None CELL LUNG CANCER (NSCLC) AND AN View
None EASTERN COOPERATIVE ONCOLOGY GROUP View
None PERFORMANCE STATUS OF 2 View
None (ABOUND.PS2) View
None LOCALLY ADVANCED OR METASTATIC NON SMALL View
None CELL LUNG CANCER (NSCLC) SUBJECTS THAT AE NOT CANDIDATES FOR … View